Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BHLHE40 Antisense RNA 1 (BHLHE40-AS1)
- Target
- BHLHE40-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein-coding RNA
01
Overview
BHLHE40 Antisense RNA 1 (BHLHE40-AS1) is a cytoplasmic, evolutionarily conserved human long non-coding RNA transcribed antisense to the BHLHE40 gene. It plays a significant role in cancer progression by promoting an immune-permissive microenvironment and supporting inflammatory signaling, notably through IL-6 and STAT3 pathway regulation. BHLHE40-AS1 is enriched in HER2-positive breast cancers and its expression correlates with increased invasiveness, decreased patient survival, and altered sensitivity to chemotherapy. Experimental reduction of BHLHE40-AS1 suppresses tumor cell growth and decreases inflammatory cytokine expression, indicating a functional role in tumorigenesis but not as a direct therapeutic target or receptor.
- Other names
- BHLHE40-AS1BHLHE40 antisense RNA 1lncRNA BHLHE40-AS1
02
Mechanism of action
Not targeted by drugs directly. Mechanistically, may interact with IL-6 mRNA via ILF3 (an RNA-binding protein), support STAT3 pathway activation, and modulate inflammatory cytokine expression.
03
Biological functions
Regulation of inflammatory cytokine signaling (e.g., IL-6/STAT3)Modulation of immune-permissive microenvironment in cancerRegulation of protein expression, including DEC1/STAT3
04
Disease associations
Cancer (notably breast and ovarian cancer)Inflammatory microenvironment in tumor progression
05
Safety considerations
Not a drug target, thus direct safety concerns do not apply; however, aberrant expression is associated with poor prognosis and tumor aggressiveness.
06
Interacting drugs
Lapatinib—indirectly modulates expression in HER2+ breast cancer cells
07
Biomarkers
Expression levels of BHLHE40-AS1 as prognostic and predictive biomarker for breast cancer progression and invasivenessExpression levels of BHLHE40-AS1 as prognostic and predictive biomarker for ovarian cancer patient survivalExpression levels of BHLHE40-AS1 as prognostic and predictive biomarker for chemotherapy drug sensitivity in papillary thyroid carcinoma
Beyond the preview
Go deeper on BHLHE40 Antisense RNA 1 (BHLHE40-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHLHE40 Antisense RNA 1 (BHLHE40-AS1).